- Home
- MCTR vs CLYM Comparison
MCTR vs CLYM Comparison
Compare MCTR & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- CLYM
- Stock Information
- Founded
- MCTR 2014
- CLYM 2018
- Country
- MCTR Hong Kong
- CLYM United States
- Employees
- MCTR N/A
- CLYM N/A
- Industry
- MCTR
- CLYM
- Sector
- MCTR
- CLYM
- Exchange
- MCTR NYSE
- CLYM NYSE
- Market Cap
- MCTR 91.8M
- CLYM 83.1M
- IPO Year
- MCTR 2025
- CLYM 2021
- Fundamental
- Price
- MCTR $6.50
- CLYM $1.19
- Analyst Decision
- MCTR
- CLYM
- Analyst Count
- MCTR 0
- CLYM 0
- Target Price
- MCTR N/A
- CLYM N/A
- AVG Volume (30 Days)
- MCTR 6.4K
- CLYM 125.8K
- Earning Date
- MCTR 01-01-0001
- CLYM 05-19-2025
- Dividend Yield
- MCTR N/A
- CLYM N/A
- EPS Growth
- MCTR N/A
- CLYM N/A
- EPS
- MCTR 0.00
- CLYM N/A
- Revenue
- MCTR $4,453,234.00
- CLYM N/A
- Revenue This Year
- MCTR N/A
- CLYM N/A
- Revenue Next Year
- MCTR N/A
- CLYM N/A
- P/E Ratio
- MCTR $5,761.71
- CLYM N/A
- Revenue Growth
- MCTR N/A
- CLYM N/A
- 52 Week Low
- MCTR $3.76
- CLYM $1.05
- 52 Week High
- MCTR $12.00
- CLYM $10.23
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- CLYM N/A
- Support Level
- MCTR N/A
- CLYM N/A
- Resistance Level
- MCTR N/A
- CLYM N/A
- Average True Range (ATR)
- MCTR 0.00
- CLYM 0.00
- MACD
- MCTR 0.00
- CLYM 0.00
- Stochastic Oscillator
- MCTR 0.00
- CLYM 0.00
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.